Navigation Links
Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
Date:4/1/2011

HYDERABAD, India, and MISSISSAUGA, Ontario, April 1, 2011 /PRNewswire/ -- Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories (NYSE: RDY), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today jointly announced that they have signed a collaboration agreement for Cloderm® (clocortolone pivalate 0.1%) Cream.  Under the agreement, Promius Pharma will make an upfront payment and pay future royalties as the consideration for the right to manufacture, distribute and market Cloderm® Cream in the United States, effective immediately.  The financial terms and conditions of the agreement have not been disclosed.

Raghav Chari, PhD, Senior Vice President, Proprietary Products and Head of Promius Pharma, said, "We are very pleased to have formed a partnership with Valeant to market Cloderm® Cream in the United States, where Promius Pharma is building a strong commercial and clinical presence.  Cloderm® Cream is a time-tested product and has strong recognition among dermatologists. The addition of this product will bolster our ongoing efforts to build a successful prescription branded franchise in the US, and specifically contribute to Promius' goal to become a leader in the field of medical dermatology."

About Cloderm® Cream

Cloderm® (clocortolone pivalate) Cream, 0.1% is a topical mid potent steroid product indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.  Cloderm Cream is available in a 45-gram and 90-gram tube, and in a 30-gram or 75-gram pump, by prescription only.  For more information, please contact your healthcare provider or Promius Pharma.  

Important Safety Information

The most common adverse events associated with Cloderm® Cream include dryness, irritation, folliculitis, itching, and burning. Cloderm® Cream is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.  See full prescribing information at www.promiuspharma.com/cloderm

Dr. Reddy's Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

Valeant Pharmaceuticals Forward-Looking Statement

This press release may contain forward-looking statements. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

About the Companies

About Dr. Reddy's

Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is a global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia.

www.drreddys.com

About Promius Pharma

Promius Pharma, located in Bridgewater, NJ, is a branded specialty company and a wholly-owned subsidiary of Dr. Reddy's Laboratories, Inc. Promius Pharma aims to be a leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients. For more information, please visit www.promiuspharma.com.

About Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at http://www.valeant.com/.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

For more information please contact:

Dr. Reddy’s Laboratories
Media:  S Rajan
rajans@drreddys.com/ +91-40- 66511725

Investors and Financial Analysts:
Kedar Upadhye
kedaru@drreddys.com /+91-40-66834297

Raghavender R
raghavenderr@drreddys.com /+91-40-66511529

Milan Kalawadia (USA)
mkalawadia@drreddys.com/  +1 908-203-4931

Valeant
Laurie W. Little
(949) 461 6002


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec 1, 2016 Research and Markets ... Delivery in Cancer - Technologies, Markets and Companies" to their ... , , ... management of cancer The market value of drug delivery ... estimates from 2015-2025 are given according to organs involved and the ...
(Date:12/2/2016)... Dec. 1, 2016 Around the corners of ... and each habitable land present over earth. Cancer has ... once in a life time this is because of ... until now. Given the steady increase in global cancer ... the spiraling healthcare costs of treatment, there is increasing ...
(Date:12/2/2016)... , Dec. 2, 2016 Allergan plc (NYSE: ... additional information on its previously announced Accelerated Share Repurchase (ASR) ... ... As previously announced, the Company entered into ... which the Company will repurchase $10 billion of its ordinary ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... Honolulu, Hawaii (PRWEB) , ... December 02, 2016 ... ... 3, 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, ... (CME) in the field of pain management. , The demand for supplemental ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... "Pro3rd ... allow FCPX editors to create versatile lower third titles with just a few clicks ... Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various styles with ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ‘Tis the season ... of $1,000 each from the National Family Partnership and the Drug Enforcement Administration as ... decorated their homes and the 10 winning schools who decorated their campuses with this ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a nationally ... of a new eating disorder treatment center location in Palm Beach Gardens, Florida.  The ... adolescents, both males and females ages 10 and older with eating disorders, including ...
Breaking Medicine News(10 mins):